Person:
Baris, Enis

Loading...
Profile Picture
Author Name Variants
Fields of Specialization
GLOBAL HEALTHCARE
Degrees
ORCID
Externally Hosted Work
Contact Information
Last updated: January 31, 2023
Biography
Dr. Enis Barış is Professor of Practice at the School of Population and Global Health, Mc Gill University, Montreal, Canada, and President of GluonMed, Global Health Consultancy based in DC. Dr. Barış has been serving as a Senior Advisor to the World Bank, the New Development Bank (NDB) and The Global Fund, subsequent to his retirement from the World Bank after two decades of service, most recently as Advisor to the HNP Global Director, and HNP Practice Manager in MENA, ECA and East Asia and the Pacific Regions. He also worked in the past as Director of Country Health Systems at the European Regional office (EURO) of the World Health Organization and as Senior Advisor for Health at the International Development Research Centre (IDRC) of Canada. He also held positions as Adjunct Professor of Health Policy at the University of Montreal and the Duke Global Health Institute. Dr. Barış holds a Medical degree (MD) from Turkey, and Masters (M.Sc.) and Doctoral (Ph.D) degrees from the Université de Montréal, Canada. He is the author/co-author of seven books, as well as over 50 peer-reviewed research papers and book chapters, pertaining the comparative health systems, health and healthcare policy, health and environment and disease control programs.

Publication Search Results

Now showing 1 - 1 of 1
  • Publication
    Assessing the Global Economic and Poverty Effects of Antimicrobial Resistance
    (World Bank, Washington, DC, 2017-06) Ahmed, Syud Amer; Baris, Enis; Go, Delfin S.; Lofgren, Hans; Osorio-Rodarte, Israel; Thierfelder, Karen
    This paper assesses the potential impact of antimicrobial resistance on global economic growth and poverty. The analysis uses a global computable general equilibrium model and a microsimulation framework that together capture impact channels related to health, mortality, labor productivity, health care financing, and production in the livestock and other sectors. The effects spread across countries via trade flows that may be affected by new trade restrictions. Relative to a world without antimicrobial resistance, the losses during 2015–50 may sum to $85 trillion in gross domestic product and $23 trillion in global trade (in present value). By 2050, the cost in global gross domestic product could range from 1.1 percent (low case) to 3.8 percent (high case). Antimicrobial resistance is expected to make it more difficult to eliminate extreme poverty. Under the high antimicrobial resistance scenario, by 2030, an additional 24.1 million people would be extremely poor, of whom 18.7 million live in low-income countries. In general, developing countries will be hurt the most, especially those with the lowest incomes.